Drugs / SYL1801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT04782271 | Mar → Dec 2021 | choroidal neovascularization | Sylentis, S.A. | Completed | Met primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05637255 | Nov 2022 → Dec 2024 | wet macular degeneration | Sylentis, S.A. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-05-05 | Sylentis, S.A. | Results Sylentis, a PharmaMar Group company, announces the positive results of the Phase IIa dose-ranging study for SYL1801 in patients with Age-Related Macular Degeneration (AMD) sylentis.com ↗
The primary endpoint was reached, a mean gain from baseline was observed in a middle dose (25mg/ml), reaching statistical significance (p = 0.045). |
| 2025-05-05 | PharmaMar | Results Sylentis, a PharmaMar Group company, announces the positive results of the Phase IIa dose-ranging study for SYL1801 in patients with Age-Related Macular Degeneration (AMD) pharmamar.com ↗
Sylentis, a wholly owned subsidiary of PharmaMar (MSE:PHM), announced topline results from the SYL1801_II study, a Phase IIa dose-ranging trial evaluating SYL1801, an investigational siRNA therapy administered via eye drops unlike other treatments which require intravitreal injection, for the treatment of neovascular Age-Related Macular Degeneration (nAMD). |
| 2022-03-14 | Sylentis, S.A. | Results Sylentis, PharmaMar Group, completes Phase I trial with SYL1801 for retinal diseases sylentis.com ↗
All administered doses of SYL1801 in ophthalmic solution form were safe and well tolerated for the duration of the clinical trial. |
| 2022-03-14 | PharmaMar | Results Sylentis, PharmaMar Group, completes Phase I trial with SYL1801 for retinal diseases pharmamar.com ↗
This study provides evidence that SYL1801 is safe and well tolerated; therefore, the Phase I has met the primary safety endpoint. |
| 2021-03-18 | PharmaMar | Regulatory Sylentis, PharmaMar Group, initiates a Phase I clinical trial with SYL1801 for retinal diseases pharmamar.com ↗
Sylentis, a wholly owned subsidiary of PharmaMar Group (MSE:PHM), has announced today the initiation of the first Phase I trial with its investigational compound SYL1801 for the treatment and/or prevention of choroidal neovascularization, a common cause of retinal diseases such as Agerelated Macular Degeneration (AMD) and diabetic retinopathy. |
| 2019-05-03 | Sylentis, S.A. | Results Sylentis (PharmaMar Group) presents its new drug for retinal diseases at ARVO sylentis.com ↗
SYL1801 administered in eye drops reduces angiogenesis (blood vessel formation) in an animal model of laser-induced neovascularization, similar to intravitreally injected anti-VEGF agents. |
| 2018-05-04 | Sylentis, S.A. | Results Sylentis presented new results for the treatment of age associated macular degeneration sylentis.com ↗
Sylentis, pharmaceutical company belonging to the PharmaMar Group (MSE:PHM), has presented the preclinical results of a new molecule (SYL1801), indicated for the treatment of age associated macular degeneration and which is administered topically. |
All press releases naming this drug 11 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYL1801 | “Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops” NCT04782271 ↗ |